Send to

Choose Destination
Cell Stem Cell. 2007 Nov;1(5):497-501.

Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.

Author information

Division of Cell and Molecular Biology, Toronto General Research Institute, Toronto, ON M5G 1L7, Canada.


Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center